Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SAB-176

Monoclonal antibody · developed by SAb Biotherapeutics

Phase 2 Most advanced trial (none active)
SABS Developer
2 Registered trials

What is SAB-176?

SAB-176 is named in the trial record as a single ascending dose study drug, studied in Influenza A H1N1 infection and PHA1A.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Infectious disease
Developer
SAb Biotherapeutics, Inc. (SABS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FSF6D46PBF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04850898 Phase 2 Influenza A H1N1 Completed SABS
NCT06435936 Phase 1 PHA1A Unknown SABS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Influenza A H1N1PHA1A

More from SAb Biotherapeutics

Follow SABS, the company behind SAB-176

See SABS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SABS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.